Sculptra® 童顏針

主頁 > 醫學美容 > 輪廓塑形 >

Sculptra® 童顏針

Sculptra® 童顏針是一種經FDA認證的聚左乳酸(PLLA)注射劑,專為改善面部因膠原蛋白流失造成的凹陷與鬆弛所設計。其原理是透過注射聚左乳酸微粒,刺激肌膚自生67%第一型膠原蛋白,讓面部輪廓逐漸恢復豐盈和彈性。Sculptra® 童顏針的效果屬於漸進式,一般在療程後數週至數月內自然顯現,且可維持25個月。

為甚麼選擇
Sculptra® 童顏針?
Sculptra® 童顏針以聚左旋乳酸(PLLA)為主要成分,這種生物相容性材料能夠被人體自然吸收,並逐步在肌膚深層激活膠原蛋白的增生。膠原蛋白是維持肌膚彈性與緊緻的關鍵,但隨著年齡增長,膠原蛋白的產量逐漸減少,導致肌膚鬆弛和皺紋的出現。Sculptra® 童顏針透過持續激活膠原蛋白的生長,從根本上解決肌膚老化問題。
膠原蛋白是構成
年輕肌膚的重要元素6-9
隨着年齡增長,肌膚會逐漸流失脂肪及膠原蛋白,令肌膚看上去不再飽滿。膠原蛋白是人體中最常見的蛋白質,有效支撐肌底結構,讓你的肌膚達到緊緻富彈性。6,8,10-13

肌膚老化的主要原因
20歲以後,膠原蛋白便會以每年1%的速度流失,隨着體內的膠原蛋白自然流失,我們亦會感到肌膚的緊緻度下降。
獨家聚左乳酸PLLA - SCA
Sculptra® 童顏針促進膠原蛋白增生獨有秘密
短至3星期開始發揮功效
效果長達25個月
Sculptra®童顏針有效改善幼紋、皺紋、坑紋等,平均短至3星期便可見效,長效持久至療程25個月備受用家滿意及推薦

適用部位
真實個案

555按摩法

官方認證 原廠正貨

Sculptra®童顏針的適用部位?

適用於撐起因膠原蛋白流失或天生性凹痕的部位如太陽穴、法令紋、蘋果肌,亦可提升下顎及腮腺,讓臉部整體線條更緊緻明顯。

Sculptra®童顏針需要多少次數及劑量?

Sculptra® 童顏針施打次數及劑量並沒有固定,需依照每個人的肌膚情況而定。在進行相關療程之前,請先諮詢具豐富經驗的顧問,根據你的肌膚老化程度、膚質及想改善的部位評估所需劑量及療程進度,確保劑量足夠並賦予你最理想、完美及自然的微塑型效果。

Sculptra®童顏針每次療程需相隔多久?

療程無須麻醉或服藥,沒有嚴重不適。在療程前可於牙骹旁放入紗布,減低牙齒或牙床位罝的不適感;療程時肌膚有機會感覺到輕微灼熱、繃緊、發麻,近骨或肌膚薄的位置感覺會較為強烈,部分人或會感到局部肌肉麻木、酸軟無力。

Sculptra®童顏針可能導致甚麼副作用?

Sculptra® 童顏針有可能導致的副作用包括暫時性的不適、發紅、膏瘀、滲血、痕痛或腫脹。

1. Kim J. Arch Aesthetic Plast Surg. 2014;20(2):97–103. 2. 3. 4. 5. 6. 7. 8. 9. Kerscher M, et al. Dermatol Surg.2008;34(5):720–726. Ribé A, et al. J Cosmet Laser Ther. 2011;13(4):154–161. Bohnert K. et al. Plast Reconstr Surg. 2019;127(4):1684-1692. Mest DR, Humble G. Dermatol Surg. 2006;32(11):1336-1345. Goldberg D, et al. Dermatol Surg. 2013;39(6):915–922. Fabi S, et al. Eectiveness and safety of correction of cheek wrinkles using biostimulatory poly-L-lactic acid injectable implant - Clinical study data up to 24 months. Poster presented at the International Master Course on Aging Science (IMCAS) World Congress, 26–28 January 2023, Paris, France Galderma. A patient’s guide to treatment with SCULPTRA®. 2021. Available from: https://www.galderma.com/us/sites/default/les/2021-12/Patient_Brochure_Sculptra_US_1.pdf Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners. Galderma. 2021. Available from: https://www.galderma.com/news/galderma-receives-fda-approval-new-sculptra-label-offering-more-options-aest hetic-partners10. Noguchi A, Djerassi D. Chapter 15 - Amino Acids and Peptides: Building Blocks for Skin Proteins, Editors: Tabor A, Blair RM, In Personal Care & Cosmetic Technology, Nutritional Cosmetics, William Andrew Publishing, 2009, Pages 287–317.11. Shoulders MD, Raines RT. Ann Rev Biochem. 2009;78:929–958.12. Aziz J, et al. Skin Pharmacol Physiol. 2016;29(4):190–203.13. Farage MA, et al. Adv Wound Care (New Rochelle). 2013;2(1):5–10.14. Shuster S, et al. Br J Dermatol. 1975;93:639–643.15. Marchado Filho CD, et al. Surg Cosmet Dermatol. 2013;5(4):345–350.16. Lacombe V. Facial Plast Surg. 2009;25(2):95–99.17. Asius J, et al. Inventors. US patent US 7,731,758 B2.2010.18. Morgan P, et al. Product Manufacturing Process for Poly-L-lactic acid (PLLA-SCA). Poster presented at the International Master Course on Aging Science (IMCAS) World Congress, 26–28 January 2023, Paris, France.19. Pre-market Approval (PMA) (fda.gov).20. Data on File (MA-54151).21. Bohnert K, et al. Plast Reconstr Surg. 2019;45(5):718–724.22. Narins RS, et al. J Am Acad Dermatol. 2010;62(3):448–462.23. Brandt FS, et al. Aesthet Surg J. 2011;31(5):521–528.24. Bartus C, et al. Dermatol Surg. 2013; 39:698-70525. FDA. Summary of Safety and Effectiveness data. Available at:https://www.accessdata.fda.gov/cdrh_ docs/pdf3/P030050S039A.pdf26. Data on File (MA-47133).27. Data on File (MA-54105).28. Brown SA, et al. Plast ReconstrSurg. 2011;127(4):1684–1692.29. Baumann. 2020.Immediate use after reconstitution of a biostimulatory poly-L-lactic acid injectable implant30. Data on File (MA-39680).31. Data on File (MA-40221).32. Data on File (MA-39613).